Once let Hengrui medicine out of sight, but now rely on the sale of housing survival, Haizheng pharmaceutical industry in the end what happened?

Guide: Haizheng pharmaceutical industry downhill still, the loss situation persists, worry!the old pharmaceutical company Zhejiang Haizheng Pharmaceutical Co., Ltd(hereinafter referred to as "Haizheng Pharmaceutical") came out to sell the house again!recently, Haizheng Pharmaceuticals announced that the five 2-unit 602-room properties located in Baima Apartment stake in Hangzhou Arch Villa District will be publicly listed through Taizhou City Property Exchange Co., Ltd., with a transaction value of 0.13 billion yuanhad to catch up with the same year listed Hengrui Pharmaceuticals well-known old pharmaceutical companies, but now it is down, Haizheng Pharmaceuticals what is the matter?for 5 consecutive years after the loss, subsidiaries are in the losspublic information shows that the old pharmaceutical company Haizheng Pharmaceuticals was founded in 1956, listed on the Shanghai Stock Exchange in 2000, Haizheng Pharmaceuticals is a raw materials pharmaceutical production enterprises, product treatment areas involving anti-tumor, cardiovascular system, anti-infection, anti-parasitic, endocrine regulation, immunosuppression, anti-depression and so onHaizheng Pharmaceuticals' performance has been growing substantially for many years after its listing, with revenuebreaking the 10 billion mark in 2014, when Haizheng Pharmaceuticals' performance outstripped that of the same year listed and the current pharmaceutical industry A-share "market value of one brother" Hengrui Pharmaceuticalsbut since 2015, the company's performance began to suffer from the history of "Waterloo", Haizheng Pharmaceuticals has been five consecutive years of non-deductible losses2015-2018, Haizheng Pharmaceuticals' net non-net profit was -139 million yuan, -283 million yuan, -141 million yuan and -612 million yuan, respectivelyin 2019, the company achieved a year-on-year profit from the return of the parent's net profit through the disposal of non-core long-term assets, but the loss of net profit after deducting the non-subsidiary expanded to 2.521 billion yuanThe Daily Financial Report also noted that in 2019, Haizheng Pharmaceuticals disclosed a total of 18 major holding companies, including Haizheng Pharmaceuticals (Hangzhou) Co., Ltd., Hanyu Pharmaceutical Co., Ltd., Zhejiang Pharmaceutical Industry Co., Ltdin these 18, only Hanyu Pharmaceutical Co., Ltd., Zhejiang Pharmaceutical Industry Co., Ltd., Zhejiang Haizheng Machinery Manufacturing and Installation Co., Ltd., Zhejiang Haikun Pharmaceutical Co., Ltd4 companies are in a profitable state, the remaining 14 are in a loss-making state, the cumulative loss of nearly 670 million yuancontinued to be depressed, the debt ratio remains high
in 2014, Haizheng Pharmaceuticals revenue exceeded the 10 billion mark for the first time, net profit in 2011 reached a peak of 504 million yuanHowever, since 2015, Haizheng Pharmaceuticals' finances began to decline, and 2016 was the first loss since the listing 2018, Haizheng Pharmaceuticals lost 492 million yuan, down 3730.15 percent year-on-year At the time, Haizheng Pharmaceuticals said that the excessive scale of fixed asset investment is one of the reasons for the continued downturn in operating performance and frequent asset sales are associated with high debt ratios In 2010, Haizheng Pharmaceuticals had less than 2 billion yuan in debt, reaching a peak of 10.239 billion yuan in 2017 is also from this time, Haizheng Pharmaceuticals on the road to sell assets, such as the transfer of several holding and equity shares in the company public data show that in 2019, Haizheng Pharmaceuticals has returned more than 3 billion yuan through the sale of assets Also in 2019, Haizheng Pharmaceuticals achieved a turnaround, with revenue of 11.072 billion yuan, up 8.68 percent year-on-year, and net profit of 930.727 million yuan 2019, Haizheng Pharmaceuticals' asset-liability ratio was 64.21%, down slightly from 66.24% in 2018, but the debt of nearly 10 billion yuan remains a problem for Haizheng Pharmaceuticals Although the year 2020 is open, the health care reform is on track, whether it is the implementation of the pharmaceutical negotiations, the implementation of the belt collection plan, or the expectation of pooling and expanding, etc., are continuing the policy direction of the major medical reform in the past year but Haizheng Pharmaceuticals entered the 2020 trend has not changed, the first quarter after the deduction is still in a loss-making state The company reported operating income of RMB2.5 billion in the first quarter of 2020, down 10.7% YoY, an increase in net profit of RMB071 million compared with the same period last year at the same time, Haizheng Pharmaceuticals' interest-bearing borrowings included short-term borrowings of $5.135 billion, long-term borrowings of $1.37 billion and bonds payable at $203 million, totalling 6.708 billion, and its asset-liability ratio remained high at 65.11 percent the living environment is still grim, selling houses to sell shares to sell peacock
in addition to the pressure of funds, Haizheng pharmaceutical industry is still facing a serious living environment In 2017-2019, Haizheng Pharmaceuticals had gross margins of 31.52 percent, 41.78 percent and 42.97 percent, respectively, according to the financial results Compared with Hengrui Pharmaceuticals, in 2017-2019, Hengrui Pharmaceuticals' gross margin was 86.63 percent, 86.60 percent and 87.49 percent, respectively has been selling assets frequently since last year to ease capital pressures because of weak debt ratios In April last year, Haizheng Pharmaceuticals announced the sale of vacant properties in Beijing, Shanghai, Hangzhou and Jiajiang last May, Haizheng Pharmaceuticals announced the intention to transfer 20.24 percent of Zhejiang Ming Pharmaceutical Technology Co., Ltd with an estimated value of 138 million yuan In July last year, Haizheng Pharmaceuticals gave up its controlling stake in Haizheng Borui and cashed in 2.828 billion yuan through a transfer of old shares In addition, Haizheng Pharmaceuticals still has a number of properties for sale November 5, 2019, Haizheng Pharmaceuticals submitted to the Shanghai Stock Exchange the listing application for rooms 1901 and 1902 rooms of the 4855 Guangfulin Road, Xiaokunshan Town, Songjiang District, Shanghai, and the 1901 and 1902 rooms of the 3rd building of Nanbinhe Road, Xuanwu District, Beijing As of December 31, 2019, Haizheng Pharmaceuticals has not solicited eligible transferees in addition to selling shares, Haizheng Pharmaceuticals also sold peacocks In September last year, Haizheng Pharmaceuticals was exposed for selling 23 peacocks raised in the park to employees at low prices The sale information only hung out a day, peacock sold out, the network 23 peacocks sold 15640 yuan but after all, the sale of idle assets of funds is not a long-term solution, the above measures, can let Haizheng Pharmaceuticals this year to achieve a turn-around profit? Where is Haizheng Pharmaceuticals next? The Daily Financial Report will continue to be watched .